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Abstract: Foremost amongst the diseases preventable by vaccination is influenza. Worldwide, 
influenza virus infection is associated with serious adverse events leading to hospitalization, 
debilitating complications, and death in elderly individuals. Immunization is considered to be 
the cornerstone for preventing these adverse health outcomes, and vaccination programs are 
timed to optimize protection during the annual influenza season. Trivalent inactivated influenza 
virus vaccines are believed to be both effective and cost-saving; however, in spite of wide-
spread influenza vaccination programs, rates of hospitalization for acute respiratory illness and 
cardiovascular diseases have been increasing in this population during recent annual influenza 
seasons. From meta-analyses summarizing estimates of influenza vaccine effectiveness from 
available observational clinical studies, this review aims to examine how effective current 
influenza vaccine strategies are in the aging and older adult population and to analyze which are 
the most important biases that interfere with measurements of influenza vaccine effectiveness. 
Furthermore, consideration is given to strategies that should be adopted in order to optimize 
influenza vaccine effectiveness in the face of immune exhaustion.
Keywords: influenza vaccine effectiveness, influenza virus infection, immunosenescence, 
hemagglutinin activity inhibition, innate immunity, hemagglutinin inhibition, older adults
Introduction
Vaccination is considered to be the cornerstone for preventing the morbidity and 
mortality associated with influenza virus infection. Immunization programs are timed 
to optimize protection during an influenza season, and in the northern hemisphere a 
system of annual identification of new strains causing illnesses, selections for vaccines, 
chick embryo growth, inactivation, processing, packaging, distribution and usage has 
been in place for decades.1 Current vaccines contain 15 µg of the hemagglutinin of 
A/H1N1, A/H3N2, and B strains, respectively, and are administered to induce serum 
antihemagglutinin antibody for prevention of subsequent infection and illness from 
natural influenza.1,2
In the USA, the Advisory Committee on Immunization Practices recommends 
universal vaccination (ie, for all persons aged $6 months) and the National Advisory 
Committee on Immunization in Canada as well.2,3 In comparison, vaccination 
guidelines within the European Union community are much more conservative.4 
The yearly influenza vaccination of at-risk individuals is still common practice, and 
elderly and chronically ill individuals, regardless of age, are the most important 
  target groups,5,6 but with discrepancies between different national government public 
health recommendations (Austria, Germany, Hungary, and Russia $60 years of age; 
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most European countries $65 years of age).7 Until now, 
European policy makers have not found enough evidence to 
target other groups, but caregivers and health care   workers 
are also strongly advised to receive vaccination.2,4 Only 
trivalent inactivated influenza virus vaccines are commonly 
used in Europe;4,8 and live attenuated vaccines, available in 
the USA since 2003, were only recently approved for use in 
Europe and are limited to persons aged 2–59 years.4 Trivalent 
inactivated influenza virus vaccines are therefore widely used 
throughout the world, with approximately 300 million doses 
produced each year.9
However, in spite of widespread influenza vaccination 
programs, vaccine coverage rates are still generally poor 
and do not meet World Health Organization targets.6 Of 
course, this could contribute to why influenza infection 
remains a major public health concern across the world.5,6,10–12 
  However, it is still unclear, as recently reviewed by Monto,6 
if a   further increase in vaccine coverage will translate into 
public health benefits. Thus, annual estimates indicate that 
influenza infections still cause 3–5 million severe cases, 
resulting in 250,000 to 350,000 deaths worldwide.1 In the 
European Union, between 40,000 and 220,000 deaths per 
year can be attributed to influenza infection, depending on the 
pathogenicity of the circulating viral strain.5 A review by the 
National Institutes of Health in 2008 concluded that seasonal 
influenza virus caused more than 200,000 hospitalizations 
and 41,000 deaths in the USA every year, and that it was 
the seventh leading cause of death.13 Older individuals and 
especially those suffering from chronic medical conditions 
or immunological disorders account for approximately 90% 
of all influenza-related deaths.6,13,14 However, mortality 
is just the tip of the iceberg in terms of disease9,15–18 and 
  economic burden (ie, amounting to $87 billion each year 
in the USA).19
It is largely believed that current influenza vaccines are 
both effective20 and cost-saving in the aged population.21,22 
However, while the trivalent inactivated influenza virus 
vaccine prevents laboratory-confirmed influenza illness in 
approximately 70%–90% of healthy adults when the vaccine 
and circulating virus are antigenically similar,23,24 the picture 
for older individuals is not as clear. Indeed, few placebo-
controlled, randomized clinical trials have been performed, 
and none have been powered enough to study severe 
outcomes, including mortality.12 This severely limits what 
such randomized clinical trials can tell us about the benefits 
of vaccination.12 The largest and best designed placebo-
controlled, randomized clinical trial was done by Govaert et al 
in The Netherlands during the 1991–1992 influenza season.25 
In that study, 1838 healthy volunteers aged $60 years were 
randomly assigned to receive either a placebo or a trivalent 
inactivated influenza virus vaccine. After stratifying by age, 
Govaert et al estimated an influenza vaccine effectiveness 
of 57% in people aged 60–69 years, but of only 23% in 
volunteers aged $70 years. This result suggests that the effect 
of the vaccine decreases further in this subpopulation, which 
partly reflects changes in the immune system occurring with 
advancing age (see Figure 1).10,11
It has not been possible to resolve this issue for obvious 
ethical reasons.10 Therefore, current influenza vaccine 
effectiveness estimates are mainly derived from observational 
studies, typically using data from research databases or health 
care utilization data systems.10,26 Based on meta-analyses 
summarizing these estimates,24,27–32 this review aims to examine 
how effective current influenza vaccine strategies are and to 
analyze which are the most important factors modulating the 
interpretation of study results. Furthermore, consideration is 
given to current and future strategies to optimize influenza 
vaccine effectiveness in this higher-risk population.
Literature search strategy
With the aim to identify all meta-analyses estimating the 
influenza vaccine effectiveness in aging and older adult 
populations, a literature search was electronically performed in 
databases via OVID (PUBMED, MEDLINE, EMBASE) from 
1990 to 2011 with the following combination of keywords: 
“(“influenza vaccin*” [MeSH Terms] OR “influenza” [All 
Fields] AND “vaccine” [All Fields]) OR (“influenza vaccine” 
[All Fields] OR (“influenza” [All Fields] AND “vaccine” [All 
Fields]) OR (“influenza vaccine” [All Fields] AND “Humans” 
[MeSH Terms] AND (“Meta-Analysis” [ptyp]). Appropriate 
publications from this research were selected on the basis of 
title/abstract and full text. Only studies of seasonal influenza 
were considered, and because live attenuated vaccines are 
not currently available in Europe, the overview was restricted 
to trivalent inactivated influenza virus vaccines. Studies 
published in languages other than English or French were 
not considered. Only randomized and controlled trials with 
clinical endpoints (efficacy and/or effectiveness versus 
placebo or no intervention) were considered. Reviews that 
were not systematic and case-control studies or cohort 
studies were not included.
What do we know about influenza 
vaccine effectiveness estimates?
Fedson et al were among the first authors to report influenza 
vaccine effectiveness against influenza-like illness in terms 
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of hospitalization and death.33 The authors reported that 
the influenza vaccine prevented 37%–39% of hospital 
admissions for pneumonia and 27%–30% of all-cause 
  mortality. Subsequent observational studies, as summarized in 
a 2002 meta-analysis,32 showed similar estimates. According 
to a recent Cochrane systematic review,28 influenza vaccine 
effectiveness in a mixed hospital and community population 
was 41% and 58%, respectively, against laboratory-confirmed 
influenza. Considering data from the French Sentinel 
Network, Legrand et al,34 who assessed yearly field vaccine 
effectiveness during the 1995–2005 epidemic seasons, 
observed a consistently lower response among older adults 
($65 years) than among people aged 15–64 years. Cases were 
defined according to criteria of influenza-like illness (sudden 
onset of fever .39°C with myalgia and respiratory signs). 
Further examination of influenza vaccine effectiveness in 
individuals aged $65 years was carried out by Rivetti et al.30 
These authors performed a review of 64 studies (randomized, 
quasi-randomized, cohort, and case-control studies assessing 
efficacy against laboratory-confirmed influenza illness cases or 
influenza-like illness). Influenza vaccine effectiveness against 
influenza-like illness was 23% (95% confidence interval 
[CI] 6–36) and nonsignificant against laboratory-confirmed 
influenza illness (relative risk [RR] 1.04; 95% CI 0.43–2.51). 
Well matched vaccines prevented pneumonia (influenza 
vaccine effectiveness 46%; 95% CI 30–58), hospital 
admission (influenza vaccine effectiveness 45%; 95% 
CI 16–64), and deaths from influenza or pneumonia (influenza 
vaccine effectiveness 42%; 95% CI 17–59). For community-
dwelling elderly, trivalent inactivated influenza virus vaccines 
were not significantly effective against laboratory-confirmed 
influenza illness (RR 0.19; 95% CI 0.02–2.01), influenza-like 
illness (RR 1.05; 95% CI 0.6–1.9), or pneumonia (RR 0.88; 
95% CI 0.6–1.2). Well matched vaccines prevented hospital 
admission for influenza and pneumonia (influenza vaccine 
effectiveness 26%; 95% CI 12–38) and all-cause mortality 
(influenza vaccine effectiveness 42%; 95% CI 24–55). 
After adjustment for confounders, vaccine performance was 
improved for hospitalization for influenza or pneumonia 
(influenza vaccine effectiveness 27%; 95% CI 21–33), 
respiratory (influenza vaccine effectiveness 22%; 95% CI 
15–28), and cardiac diseases (influenza vaccine effectiveness 
24%; 95% CI 18–30), and for all-cause mortality (influenza 
vaccine effectiveness 47%; 95% CI 39–54). The results 
also demonstrated that vaccination was most effective for 
individuals living in institutional settings, and the usefulness 
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Figure 1 Development of immunosenescence with advancing age and its impact on the ability of the immune system to respond to influenza virus antigen. Potential 
impacts of immunotherapy of immunosenescence are also presented.
Abbreviations: CMV, cytomegalovirus; IL, interleukin; TIV, trivalent inactivated influenza vaccine; TNF-α, tumor necrosis factor-alpha.
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of vaccines in the community was modest. Similar results 
were observed from a study conducted by Nichol et al.20 
The influenza vaccine appeared 49% and 32% effective in 
preventing hospitalizations from pneumonia or influenza and 
55% and 64% effective in preventing death from any causes 
among older adults at low or intermediate risk, respectively. 
Among older adults at higher risk due to comorbid health 
conditions, vaccination is 29% and 49% effective in preventing 
death and hospitalization, respectively. Thus, when influenza 
vaccine effectiveness among adults is stratified by both age 
and health status, a different picture emerges in the elderly 
population. Indeed, in most observational studies, adjustment 
for underlying health conditions further increased estimates 
of influenza vaccine effectiveness.4,10,20,28,35–42
Why are the overall benefits  
of influenza vaccination still hotly 
debated?
While administrative data sets are recognized as an   efficient 
method to estimate influenza vaccine effectiveness, this is 
potentially prone to intractable bias,12,43–48 and   therefore 
the validity of estimates derived in this way appears 
questionable.49 Similarly, observational immunogenicity 
studies do not seem to provide clearer and stronger   outcomes.50 
The significance of an early decrease in primary antibody 
responses (ie, antihemagglutinin antibody responses induced 
in previously unvaccinated persons) noted in older adult 
populations compared with their younger counterparts is also 
highly debated.51,52 Finally, both approaches highlight serious 
methodological flaws, ie, variation in definition of influenza 
cases, use of different clinical endpoints, poor   correlates of 
protection in immunogenicity studies, and potential bias that 
affect the estimates of influenza effectiveness (being failure 
to exclude participants with conditions that have an influence 
on the immune response, those previously vaccinated, and 
those with high prevaccination titers).11,53
Which factors may interfere 
with measurement of vaccine 
effectiveness?
Accurate assessment of influenza vaccine effectiveness can 
be a challenge due to varying case definitions, use of different 
clinical endpoints, and poor correlates of protection in 
immunogenicity studies.9 Diagnostic tests for influenza have 
varying levels of sensitivity and specificity for influenza-
like illness, and this must be considered when interpreting 
case definitions and the correlation with overall burden of 
the disease.9 Further complications in diagnosis can occur 
due to the large number of patients with influenza-like illness 
who are culture-negative (40%).23,54,55 This further distorts 
the true extent of the disease burden. When interpreting the 
findings from observational studies, it is very important to 
consider not only mortality and hospitalization rates but also 
other important health outcomes, such as exacerbation of 
chronic comorbid health conditions, secondary infections that 
result in physician visits, antibiotic use, and disability.43,45,46,56 
Influenza is also a major contributor to functional physical 
decline,18 and causes exacerbations of pulmonary and cardio-
vascular disease.9,15 It is also the primary cause of increased 
mortality among patients with underlying chronic comorbid 
conditions (ie, acute ischemic heart disease, stroke, and 
pneumonia) in the winter season.37,57,58
Serologic markers are a complex surrogate of influenza 
vaccine effectiveness, and notably when birth cohorts 
are compared. Indeed, the influenza vaccine is constantly 
changing, and intercohort differences in priming history 
with regard to one or another of the variants result in 
extreme heterogeneity in baseline influenza serology.52 
Thus, most adults have pre-immunization serum antibody 
levels and this is because of prior influenza infections and/
or vaccinations, and this affects the serum antihemagglutinin 
titer and the B cell response to subsequent vaccination. 
Therefore, the humoral immune responses of young and 
older adults often differ markedly for some influenza strains 
(eg, A/H1N1 that circulated between 1918 and 1957 and 
was reintroduced in 1976) but are more similar for others 
(eg, A/H3N2 that has circulated since 1968).10 When these 
differences are taken into account, the elderly appear capable 
of mounting and maintaining antibody responses similarly 
to those of younger adults. This is well illustrated by the 
results of a study conducted by Yu et al,59 who showed 
that people born in or before 1915 and had brothers and/
or sisters who died during the influenza outbreak of 1918 
possessed highly functional, virus-neutralizing antibodies 
to the 1918 H1N1 virus, nearly 90 years after the pandemic. 
Therefore, variation in antibody response to vaccination 
may possibly be attributed to priming experience rather 
than imaging of the immune system per se. This has also 
been demonstrated in a recent cross-sectional serological 
survey conducted in England.60 In 1403 baseline serum 
samples from 2008 (before the first wave of H1N1 infection), 
the proportion of samples with an antihemagglutinin titer 
1:32 or more (deemed a protective response) ranged from 
1.8% in children aged 0–4 years to 31.3% in adults aged 80 
years or older. In addition, the proportion of samples with 
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an hemagglutination inhibition titer $1:32 between baseline 
and September 2009 (after the first wave of infection), was 
21.3% for children younger than 5 years of age, 42.0% for 
children aged 5–14 years, and 20.6% for those aged 15–24 
years, with no difference between baseline and September 
in older age groups. However, while the antigen mismatch 
has important effects on the serum antibody level,59,61,62 this 
does not necessarily mean that the immune response is not 
effective.63–65 Indeed, as recently showed by Sasaki et al,65 
the inferior antibody response to influenza vaccination in 
the elderly is primarily due to reduced quantities of vaccine-
specific antibodies rather than a lack of antibody avidity 
and activity. Instead, this clear inverse relationship between 
preimmunization serum antibody levels and antibody 
increase after vaccination leads to an underestimation of 
influenza vaccine effectiveness when the antihemagglutinin 
titer is used as a surrogate maker of protection and the 
increase in antihemagglutinin titer as a measure for predicting 
vaccine efficacy.10,11,50
Evidence of bias in estimates  
of influenza vaccine effectiveness
All meta-analyses summarizing estimates of influenza 
vaccine effectiveness have questioned the quality and 
interpretation of available data.24,27–32 This suggests that 
biases may be partially or even completely responsible for 
estimates of influenza vaccine effectiveness.10,12,26,43,45–47,66,67 
Jackson et al have assessed the risk of death from any 
cause and hospitalization for pneumonia or influenza in 
relation to vaccination in periods before, during, and after 
influenza seasons.45 The results indicated preferential receipt 
of vaccine by relatively healthier seniors. Furthermore, 
adjustment for comorbid health conditions did not control 
for this bias. These findings have also been noticed by 
others.12,26,45–48 Thus, a curvilinear relationship between 
predictors of mortality and vaccination has been depicted,67 
with the propensity to obtain vaccine waning with the risk 
of mortality due to comorbid conditions. Furthermore, 
functional limitations, such as requiring assistance for 
bathing for example, have been demonstrated to be 
associated with a decreased likelihood of vaccination, even 
in aged persons free of comorbid conditions.46 Overall, these 
findings suggest that near the end of life, disability appears 
to be a contributing factor in the decision to receive or not 
to receive the vaccine.10 Thus, pre-influenza season analyses 
seem to introduce biases that may not be present in influenza 
season analyses.41 Indeed, observational studies generally 
select subjects who are appropriate candidates for the 
intervention, who all have similar access to the intervention. 
Thus, persons known to have a short life expectancy may not 
be offered the vaccine, or may have fewer opportunities to 
get vaccinated compared with individuals who are relatively 
healthy throughout the vaccination season.20 In addition, 
the retrospective assessment of functional status is also a 
finding leading to a healthy vaccinee bias in observational 
studies.46 Further findings from Fireman et al showed that 
after having adjusted for risk factors (ie, older age, chronic 
conditions, and self-reported health status) mortality before, 
during, and after nine influenza seasons increased by a 
similar trajectory over time in both healthier individuals 
and subgroups at high-risk of death.67 Interestingly, a recent 
study44 has returned to one of the linked population databases 
by which vaccine effectiveness against hospitalization and 
death in the elderly was first assessed.33 Exploring influenza 
vaccine effectiveness across six influenza seasons (including 
periods before, during, and after peak activity), the authors 
demonstrated that changes in immunization habits relative 
to the preceding years may be a readily accessible and 
recognizable bias.44 This study illustrates the profound 
noncomparability of immunized and nonimmunized 
elderly which is not corrected, but rather is exacerbated, by 
adjustment for standard confounders. Thus, individuals who 
were previously immunized and continued to receive the 
influenza vaccine experienced the lowest hospitalization and 
mortality rates across all analysis periods; those previously 
immunized and then not undergoing immunization had a 
significantly higher likelihood of both hospitalization and 
death that was evident in advance of the influenza period. 
Conversely, those who were previously and again immunized 
were at significantly lower risk at all times. Further, those 
choosing to be newly vaccinated were at significantly higher 
risk for hospitalization but not death before and during the 
influenza season. All these findings provide strong evidence 
that selection bias is a fatal flaw in many observational 
estimates in the elderly, and these results do not provide 
valid evidence on which to estimate the true benefit that may 
be derived from influenza vaccination campaigns. Finally, 
accurate assessment of influenza vaccine effectiveness from 
observational studies is a more arduous and challenging 
task than initially expected. This was recently confirmed 
by systematic reviews of existing literature (randomized   
and quasi-randomized controlled trials comparing influenza 
vaccines with placebo or no intervention in naturally 
occurring influenza or relevant reviews) in healthy elderly 
and older adults with comorbidities or the institutionalized 
elderly.4,10,24,28,44,50
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Can we properly differentiate a true 
vaccine effect from biases?
To differentiate vaccine effects from biases, Fireman et al 
have proposed a “difference in differences” approach.67 In 
other words, if the influenza vaccine really does prevent 
deaths, then in a large population there should be a 
detectable difference between the difference in the odds 
of prior vaccination between decedents and survivors that 
is observed on days when influenza is circulating and the 
difference in the odds of prior vaccination between decedents 
and survivors that would be expected on the same calendar 
dates if influenza were not circulating. Hence, influenza 
vaccine effectiveness reduced all-cause mortality among aged 
adults by 4.6% during the 1996–2005 laboratory-confirmed 
influenza seasons.67 Whereas it has been found by Simonsen 
et al that influenza infections accounted at most for 10% 
of all deaths during the influenza season,12 many cohort 
studies reported a 50% reduction in the total risk of death in 
winter.20,38 However, as recently discussed by Nichol,56 the 
accurate excess deaths/winter-time deaths ratio attributable 
to influenza is challenging to estimate, due to the lack of 
available measures at the individual level. This ratio uses a 
numerator that underestimates influenza-associated deaths 
due to the difficulty in understanding the true disease burden 
caused by influenza and a denominator that overestimates 
deaths during the influenza season.56,68 As a result, this ratio 
does not accurately reflect the absolute mortality burden 
attributable to influenza, and is therefore a misleading number 
for judging the plausibility of influenza vaccine mortality 
benefit. Similarly, in a recent large population-based nested 
case-control study, which incorporated a seasonal analysis, 
influenza vaccination was not significantly associated with a 
reduction in the risk of community-acquired pneumonia in the 
aged population.48 While the influenza vaccine effectiveness 
estimate is consistent with approximations from two recent 
meta-analyses demonstrating influenza vaccine effectiveness 
against pneumonia hospitalization,30,32 the width of its 
confidence interval demonstrates imprecision and a lack of 
statistical power.10
Thus, the influenza vaccine benefits “controversy” arises 
from questions about whether residual confounding and 
biases in observational studies have resulted in influenza 
vaccine effectiveness estimates that misjudge the true benefit. 
Without dramatic modification, the current adjustment 
methods will not adequately control for bias, and the 
controversy will undoubtedly continue. New strategies 
are needed to improve the accuracy of influenza vaccine 
effectiveness estimates. Future studies should include 
exploring the strengths and limitations of various comparison 
periods for model validation, the influence of important 
potential confounders, and other methods to quantify the 
impact of potential residual confounding such as sensitivity 
analyses.56 Complementarily, approaches for reducing bias 
should include obtaining more accurate information on 
confounders, such as functional status and life expectancy, 
avoiding all-cause death in favor of outcomes such as 
pneumonia or influenza-related pneumonia, and include 
prospective ascertainment of influenza-specific outcomes 
to improve study sensitivity to detect a true vaccine effect.26 
However, no analytic technique explored could adjust for 
change in immunization habit, and therefore improved 
methods to achieve valid interpretation of protection in the 
elderly are needed.44 In order to improve influenza vaccine 
effectiveness, age-related changes in the immune system 
should also be considered. However, while immunosenes-
cence is undoubtedly a very real and important phenomenon 
that adversely influences vaccine response,49,69–71 how it 
should be measured and how exactly it influences changes 
in clinical protection is still poorly understood.10,72
Vaccination of elderly in the face  
of immune exhaustion: next steps?
This review has demonstrated that the achievement of an 
accurate assessment of influenza vaccine effectiveness is 
fraught with considerable methodological and epidemiological 
challenges. Alternatively, as current trivalent inactivated 
influenza virus vaccines do not offer optimal direct protection 
to older adult populations, protecting them indirectly through 
the effect of herd immunity or enhancing their immune 
response in order to offer higher and broader protection could 
be interesting strategies (see Figure 1).9,72,73
Beneficial effects of herd immunity 
in this ever increasing aging 
population?
While most vaccines are designed primarily to protect 
immunized individuals directly, the knockon effect on close 
contacts, neighbors, and even at the community level when 
sufficient numbers of the population have been immu-
nized, is protection from the disease. This process, which 
has been measured and termed “herd immunity,” results   
in a lower infection rate among unimmunized individuals 
for infections that are transmitted from person-to-person, 
such as influenza.73,74 Thus, not everyone needs to be immu-
nized to control the disease, and individuals who fail or 
reject vaccination or for whom vaccination is less effective, 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
60
Lang et alClinical Interventions in Aging 2012:7
ineffective, or   contraindicated would be protected indirectly. 
The protection afforded by vaccination of older individuals is 
frequently incomplete because of impaired immune function 
and/or comorbid conditions,73 so vaccination of health care 
workers (including ancillary staff and informal caregivers) 
has been recommended as an additional or alternative strat-
egy.73 High vaccine coverage rates of influenza immunization 
in health care workers in extended care facilities may result 
in lower patient mortality and influenza-like illness.75–80 
Ho  wever, a recent systematic review of randomized controlled 
trials performed by Thomas et al75,76 concluded that no effect 
was shown for specific outcomes (ie, laboratory-confirmed 
influenza, pneumonia, and death from pneumonia) while an 
effect was shown for nonspecific outcomes (ie, influenza-like 
illness, general practitioner consultations for influenza-like 
illness, and all-cause of mortality in 60+ individuals). How-
ever, these nonspecific outcomes are difficult to interpret, 
and these studies suffer from similar limitations and biases to 
those we have previously mentioned. Moreover, some health 
care workers remain unvaccinated because they do not per-
ceive influenza infection to be disabling and life-threatening, 
doubt vaccine efficacy, and are seriously concerned about side 
effects.81 The vaccine coverage rate was 51% in hospitals in 
which health care workers were routinely offered vaccine 
compared with only 5% in those in which they were not.82 
This probably explains why mandatory immunization would 
be the best strategy for increasing the vaccine coverage rate 
in the health care worker population.81
Providing stronger stimulus  
for weakening immune response
Stimulation of a primary immune response following 
  vaccination involves the activation of naive lymphocytes by 
antigen and their differentiation into memory T and B cells 
and antibody-secreting plasma B cells. Long-term immunity 
is assured by memory cells in the blood and lymph 
nodes, as well as by long-lived plasma cells and mem-
ory T cells in the bone marrow.83 As depicted in Figure 1, with 
immunosenescence, older individuals have fewer naive B and 
T cells, more memory cells, and an ever increasing number 
of senescent cells which are known to exert a regulatory role 
in vivo.10,50,73,83 Assuming the immune response becomes 
gradually weaker with age and immune cells requires a 
stronger stimulus, novel vaccine formulations have been 
tested.8,50 While currently licensed adjuvant (MF59, AS03), 
intradermal, or higher-dose vaccines (15 µg of hemagglutinin 
versus 30 or 60 µg) enhance vaccine immunogenicity mod-
estly, it is not yet clear how this will translate into protection 
against all usual influenza-associated outcomes. Safety and 
tolerability evaluations showed that solicited injection site 
reactions and systemic adverse events were however more 
frequent but were typically mild and transient.8 Moreover, 
these alternative strategies mainly focus on the initial steps 
of the immunological process of the vaccine response, and 
therefore overstimulate the naive cell pool that is reduced 
the most during the immunosenescence process,83 without 
consideration of the pool that affects the immune response 
the most, ie, senescent cells.73
Identify the problem and fix it
Because thymic atrophy is the main preceding event in all 
cases of immunosenescence,10 different ways have been 
explored regarding how best to rejuvenate the peripheral 
T cell pool and delay or reverse the immune decline.72 The 
different approaches of rejuvenating can be categorized into 
the “3Rs” of rejuvenation, ie, restoration, replacement, and 
reprogramming (see Figure 1).72 Restoration strategies aim 
to maintain a normal thymic environment by using cytokines, 
growth hormone, sex steroids, growth factors, and nutrients 
that are considered as potential immune rejuvenators. 
Replacement strategies aim to restore lost immune function 
by several techniques, including the transfusion of   autologous 
blood derived from an individual during their early life and 
transfused when they are much older. Such an approach 
involves the long-term storage of blood-derived lympho-
cytes, much as is currently done for cord blood stem cell 
  banking. Alternatively, restoration can involve transferring 
ex   vivo-generated naive T cells into individuals with defective 
  thymopoiesis or applying the adoptive transfer procedure 
usually used in hemopoietic stem cell transplantation. 
Finally, and probably the most   “revolutionary” treatment, 
could involve reprogramming the ageing immune system. 
Thus, pharmacologic approaches to enhance telomerase are 
currently being addressed as a possible means for prevention 
or retardation of replicative senescent cells.50 In addition, it 
has also been proposed to physically remove senescent cells 
from the circulation and/or induce apoptosis with the hope 
of inducing homeostatic expansion of a more functional 
population of memory T cells.10
Although the 3Rs have only been achieved in experimental 
systems, they raise questions regarding their future translation 
into the clinic.72 How could immunosenescent individuals or 
those who are at risk for immunosenescence be identified? 
What would be an appropriate point of intervention depending 
on one’s susceptibility rating? Even though a selection 
of promising parameters could provide a guideline for an 
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individual’s immunosenescence status, no testable hypothesis 
to approach the difficult definition of immunosenescence is 
currently available.73
Conclusion
Rising death and hospitalization rates due to influenza over 
recent decades in spite of a substantial increase of trivalent 
inactivated influenza virus vaccine coverage rates among the 
elderly greatly contrast with initial described benefits from 
influenza vaccination in this population. Beyond the lack of 
methods able to deal properly with bias that interfere with the 
accuracy of influenza vaccine effectiveness measurement, this 
review calls for a greater understanding of how age-related 
changes and their interaction with common chronic comorbid 
conditions interfere with the vaccine response. In addition, 
and in order to validate future influenza vaccines and/or 
immunological therapeutic approaches enhancing protection 
in this population in head-to-head clinical trials, there is still 
no gold standard against which to predict the impact of aging 
on vaccine response. Moreover, while immunosenescence 
undoubtedly interferes with the ability of the immune system 
to respond properly to vaccination, predicting individual 
responsiveness using strong biological makers that distin-
guish between healthy and immunosenescent states is also 
desirable.
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